Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Gastroenterology. 2020 Oct 29;160(3):781–796. doi: 10.1053/j.gastro.2020.10.036

Figure 1. Early anti-PD-1 treatment inhibits tumor growth in GAS-KO mice.

Figure 1.

(A) Expression of Pdl1 and Pdcd1 in the antrum following Hf/MNU by qPCR (n = 4/group).

(B) E-cadherin and PD-L1 immunostaining on Hf/MNU/GAS-KO tumors at 30 weeks post-MNU.

(C) Experimental design for early treatment.

(D-E) Gross images (D) and tumor area measured (E) from GAS-KO mice treated with isotype control (n = 8) or anti-PD-1 (n = 6). Dotted lines indicate tumor area.

(F) CD3 immunostaining on treated tumors.

(G-H) The proportion of tumor-infiltrating CD3+ T cells (G) and the subsets (H) among CD45+ cells in treated mice (n = 3-4/group) by flow cytometry.

(I) CD11b immunostaining on treated tumors.

(J-K) The percentage of intratumoral MDSCs (CD11b+Gr-1+) (J), M-MDSCs (CD11b+Ly6ChiLy6G−) and PMN-MDSCs (CD11b+Ly6CloLy6G+) (K) among CD45+ cells from treated mice (n = 3-4/group).

(L) Immunosuppressive activity of PMN-MDSCs isolated from tumors (n = 3/group). Statistically significant differences from No MDSC group.

(M-N) The proportion of macrophages (CD11b+Gr-1−F4/80+) among CD45+ cells (M) and Tregs (CD25+Foxp3+) in CD4+ T cells (N) in treated tumors (n = 3-4/group).

Scale bars, 100 μm (B); 5 mm (D); 50 μm (F and I). Mean ± SEM. one-way ANOVA (A); Student’s t-test (E, G-H and J-N). *P < .05; **P < .01; ***P < .001.